Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Gains from Sales and Divestitures (2021 - 2025)

PAVmed (PAVM) has 5 years of Gains from Sales and Divestitures data on record, last reported at $261548.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures changed N/A year-over-year to $261548.0; the TTM value through Sep 2025 reached $261548.0, changed N/A, while the annual FY2024 figure was $26912.0, 91.15% down from the prior year.
  • Gains from Sales and Divestitures reached $261548.0 in Q3 2025 per PAVM's latest filing, up from $2032.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $541666.0 in Q2 2022 and bottomed at $1016.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 5 years is $186746.9, with a median of $125000.0 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 219.91% in 2022, then plummeted 96.22% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $150000.0 in 2021, then increased by 12.88% to $169320.0 in 2022, then surged by 79.53% to $303980.0 in 2023, then plummeted by 91.15% to $26912.0 in 2024, then surged by 871.86% to $261548.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $261548.0 in Q3 2025, $2032.0 in Q2 2025, and $1016.0 in Q1 2025.